Chris Tompkins

In addition to being the Chief Technology Officer, Chris Tompkins has twenty years of pharmaceutical and biotechnology industry experience focused in the areas of process development, operations and the commercialization of new technologies. Dr. Tompkins past experience includes COO at Evia Medical, Vice President of Operations and Chief Compliance Officer at Atrius Bioscience, General Manager of Proligo LLC, and other executive roles at Proligo. Dr. Tompkins has also lead projects and performed engineering development for two marketed pharmaceutical products; at NeXstar Pharmaceuticals, he led the development team and designed the reactor technology for the macular degeneration treatment, Macugen™; and at Hoffmann-La Roche he was jointly responsible for the development and scale-up of the 5-FU pro-drug Xeloda™. Dr. Tompkins graduated with a Bachelor of Science degree in Chemical Engineering from the University of Michigan and a Ph.D. in Chemical Engineering from North Carolina State University.